Skip to main content

Table 1: Sample characteristics

From: Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration

ADNI Sample
(N = 708)
CN
(n = 221)
MCI
(n = 414)
AD
(n = 73)
p-value
Age (M/SD) 74.25 (6.08)b 71.82 (7.45)a,c 74.17 (8.37)b < 0.001
Gender (male/female)) 115/106 244/170 38/35 0.190
Education (M/SD) 16.36 (2.73)c 16.14 (2.74)c 15.18 (3.06)a,b 0.007
Follow-up in years (M/SD) 4.89 (2.5)b,c 4.24 (1.81)a,c 2.15 (0.44)a,b < 0.001
ApoE4-status (pos./neg.) 55/166 203/211 60/13 < 0.001
ApoE-alleles (22/23/33/24/34/44) 0/30/136/1/50/4 0/28/183/6/148/49 0/0/13/2/36/22 < 0.001
Amyloid-status (pos./neg.) 72/148 245/169 73/0 < 0.001
CSF-Aβ1–42 (M/SD) 1243.25 (421.93)b,c 976.67 (444.52)a,c 545.03 (159.15)= < 0.001
CSF-p-tau181 (M/SD) 21.97 (9.24)b,c 27.55 (14.27)a,c 36.77 (14.33)a,b < 0.001
CSF sTREM2 (M/SD) 4258.60 (2183.71) 4094.56 (2104.86) 4370.51 (2194.07) 0.465
ADNI-MEM (M/SD) 1.07 (0.58)b,c 0.23 (0.67)a,c −0.84 (0.50)a,b < 0.001
ADAS13 (M/SD) 9.08 (4.33)b,c 15.80 (6.61)a,c 28.82 (6.88)a,b < 0.001
MMSE (M/SD) 29.11 (1.14)b,c 27.80 (1.78)a,c 23.12 (1.89)a,b < 0.001
  1. CN Cognitively Normal, MCI Mild Cognitive Impairment, MMSE Mini-Mental State Exam, ADNI-MEM Alzheimer’s disease Neuroimaging Initiative - memory composite, a = sig. Different from CN, b = sig. Different from MCI, c = sig. Different from Dementia